regulatory status raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-23 and is reviewed periodically as new material appears.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
5α-Reductase inhibitors are inhibitors of the enzyme 5α-reductase, and are a type of specific androgen synthesis inhibitor. 5α-Reductase is an enzyme that is responsible for the conversion of testosterone into the more potent androgen dihydrotestosterone (DHT). There are three different isoforms of 5α-reductase, types 1, 2, and 3, and these three isoforms show different patterns of expression in the body. Relative to testosterone, DHT is about 2.5- to 10-fold more potent as an agonist of the androgen receptor. As such, 5α-reductase serves to considerably potentiate the effects of testosterone. However, 5α-reductase is expressed only in specific tissues, such as skin, hair follicles, and the prostate gland, and for this reason, conversion of testosterone into DHT happens only in certain parts of the body. Furthermore, circulating levels of total and free DHT in men are very low at about one-tenth and one-twentieth those of testosterone, respectively, and DHT is efficiently inactivated into weak androgens in various tissues such as muscle, fat, and liver. As such, it is thought that DHT plays little role as a systemic androgen hormone and serves more as a means of locally potentiating the androgenic effects of testosterone in a tissue-specific manner. Conversion of testosterone into DHT by 5α-reductase plays an important role in male reproductive system development and maintenance (specifically of the penis, scrotum, prostate gland, and seminal vesicles), male-pattern facial/body hair growth, and scalp hair loss, but has little role in other aspects of masculinization.
==== United States ==== 3,4-DMA is not an explicitly controlled substance in the United States, but can be considered a Schedule I controlled substance as a positional isomer of 2,5-dimethoxyamphetamine (2,5-DMA) in this country.
In medicine, treatment that experts agree is appropriate, accepted, and widely used. Health care providers are obligated to provide patients with the best practice. Also called standard therapy or standard of care. (NCI) Bias
Sources: en.wikipedia.org
For services to the Bangladeshi Community and to Charity. Elinor Muriel Middlemiss. Chef de Mission, Scotland Commonwealth Games Team. For services to Sport. Christopher Neill Middleton. Operational Delivery Deputy Director, Home Office. For Public and Voluntary Service. Steven Richard Miller. Director of Culture and Heritage, Head of Norfolk Museums Service, Norfolk County Council. For services to Heritage and Tourism. Louisa Jane Mitchell. Chief Executive, West London Zone (WLZ). For services to Children and Young People. Stephen Moffitt. Chief Executive Officer, A New Direction. For services to the Arts and Culture. Alison Jane Moffitt-Robinson. For services to Sports Management and Development in Northern Ireland. Huda Mohamed Yassin. Female Genital Mutilation Specialist Lead Midwife, Whittington Health NHS Trust. For services to Midwifery. Kathryn Ann Morley. Lately Chief Executive Officer, OnSide. For services to Young People. Fiona Bennett Morrison. Lately Community Fund Manager, Scottish and Southern Electricity Renewables. For services to the community in the Scottish Highlands. Doreen Lilian Mortimer. Volunteer Shop Manager, Tenby Lifeboat Station, Royal National Lifeboat Institution. For Voluntary Services. Andrew Bernard Moseley. Service Leader, Department for Work and Pensions. For public service in South East Wales. Peter Mountford. Lately Executive Chairman, Heropreneurs. For voluntary services to Armed Forces Personnel. Denise Murdoch. Senior Operations Manager, Carr Gomm. For services to Older People in Argyll and Bute. Alison Margaret Murray.
== Organization == Clinical pathologists are often medical doctors. In some countries in South America, Europe, Africa or Asia, this specialty can be practiced by non-physicians, such as Ph.D. or Pharm.D. after a variable number of years of residency.
Insectivores which fed on unsupplemented invertebrates have been found to suffer from vitamin A deficiencies, and a study of panther chameleons (Furcifer pardalis) found vitamin A deficiency shortened life spans and reduced reproduction rates. Turkestan cockroaches are rich in vitamin B12.
=== By function === Steroids function in a wide variety of physiological processes, including metabolism, inflammation regulation, immune response, reproduction, and cellular signaling. Their effects are mediated primarily through binding to specific intracellular receptors, which then influence gene transcription and protein synthesis. Steroids can be broadly classified by their primary biological roles, with the major classes of steroid hormones illustrated below, along with prominent members and examples of their functions.
Sources: en.wikipedia.org
Medical microbiology, the large subset of microbiology that is applied to medicine, is a branch of medical science concerned with the prevention, diagnosis and treatment of infectious diseases. In addition, this field of science studies various clinical applications of microbes for the improvement of health. There are four kinds of microorganisms that cause infectious disease: bacteria, fungi, parasites and viruses, and one type of infectious protein called prion. A medical microbiologist studies the characteristics of pathogens, their modes of transmission, mechanisms of infection and growth. The academic qualification as a clinical/Medical Microbiologist in a hospital or medical research centre generally requires a Bachelors degree while in some countries a Masters in Microbiology along with Ph.D. in any of the life-sciences (Biochem, Micro, Biotech, Genetics, etc.). Medical microbiologists often serve as consultants for physicians, providing identification of pathogens and suggesting treatment options. Using this information, a treatment can be devised. Other tasks may include the identification of potential health risks to the community or monitoring the evolution of potentially virulent or resistant strains of microbes, educating the community and assisting in the design of health practices. They may also assist in preventing or controlling epidemics and outbreaks of disease.
== Biomedical == A major metabolite in humans is 5-hydroxymethyl-2-furoic acid (HMFA), also known as Sumiki's acid, which is excreted in urine. HMF bind intracellular sickle hemoglobin (HbS). Preliminary in vivo studies using transgenic sickle mice showed that orally administered 5HMF inhibits the formation of sickled cells in the blood. Under the development code Aes-103, HMF has been considered for the treatment of sickle cell disease.
=== Phylogenetics and modern definition === By the early 21st century, vertebrate paleontologists were beginning to adopt phylogenetic taxonomy, in which all groups are defined in such a way as to be monophyletic; that is, groups which include all descendants of a particular ancestor. The reptiles as historically defined are paraphyletic, since they exclude both birds and mammals. These respectively evolved from dinosaurs and from early therapsids, both of which were traditionally called "reptiles". Birds are more closely related to crocodilians than the latter are to the rest of extant reptiles. Colin Tudge wrote:
== January 31, 1982 (Sunday) == The documentary Let Poland be Poland was televised around the world and reportedly watched by 185,000,000 in 50 nations. Hosted by Charlton Heston in the U.S., the show included appearances by Paul McCartney, Orson Welles, Henry Fonda, Kirk Douglas, Max von Sydow, James A. Michener, Glenda Jackson, Madeleine Albright and the song "Ever Homeward", sung by Frank Sinatra. The show also featured recorded segments from world leaders, including U.S. President Ronald Reagan, UK Prime Minister Margaret Thatcher, German Chancellor Helmut Schmidt, Japanese premier Zenkō Suzuki, French President François Mitterrand, and prime ministers Pierre Trudeau (Canada), Arnaldo Forlani (Italy), Adolfo Suárez (Spain), Kåre Willoch (Norway), Bülend Ulusu (Turkey), Francisco Pinto Balsemão (Portugal), Wilfried Martens (Belgium), Pierre Werner (Luxembourg) and Gunnar Thoroddsen (Iceland). The Statute of Autonomy of the Principality of Asturias went into effect, recognizing the right of self-government of the Spanish region of 78 municipalities in areas formerly occupied by the medieval Kingdom of Asturias, including the capital, Oviedo. Spain's province of Santander was renamed Cantabria
Thatcher wrote "I will not tolerate failure in this area" in the margin of the report and in the summer of 1982 a new committee was set up under Willie Whitelaw, only to come to much the same conclusion (The eventual solution, a "poll tax", was rejected both by the Green Paper and by Whitelaw's committee). Heseltine resisted demands by Leon Brittan, the Chief Secretary to the Treasury with whom he already enjoyed a somewhat antagonistic relationship, that central government have power to cap the spending of local authorities. He argued that the worst offenders were the large metropolitan counties (which, ironically, he had helped to create a decade earlier) and that the simplest solution was simply to abolish them. In the event, the 1983 manifesto, after Heseltine had moved to his next job, committed the Conservatives both to abolition of the metropolitan boroughs and to rate capping. When Heseltine objected after the election, Thatcher gave him "one of the most violent rebukes I have ever witnessed in Cabinet" according to Jim Prior, who believed that the issue helped fuel the hostility between Heseltine and Thatcher and Brittan, which would later exhibit itself as the Westland Affair. In opposition, in the late 1970s, Heseltine had been committed to reducing central government control over local government. In the 1980s, the opposite happened, with no less than 50 Acts of Parliament reducing the powers of local government. In Crick's view, although he opposed both rate capping and the poll tax, the overall trend towards centralisation was too strong for him to resist.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.